01HLX-101
Inherited retinal disease. Phase II, enrolling.
Helix designs precision gene therapies for rare inherited diseases, with two programmes now in clinical trials.
2018
Every programme starts with a family waiting for an answer.
Founded by scientists from the University of Cambridge, Helix now employs ninety people across research and clinical development.
01Inherited retinal disease. Phase II, enrolling.
Programmes in clinic
Rare metabolic disorder. Phase I/II.

Neuromuscular disease. IND-enabling studies.
Next-generation capsids designed with machine learning.

Tell us what you have in mind. A director will reply personally within one working day.